ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TRIZIVIR
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TRIZIVIR Rx

Generic Name and Formulations:
Abacavir (as sulfate) 300mg, lamivudine 150mg, zidovudine 300mg; tabs.

Company:
GlaxoSmithKline

Therapeutic Use:

Indications for TRIZIVIR:

HIV-1 infection.

Adults and Children:

<40kg: not recommended. ≥40kg: 1 tab twice daily.

Contraindications:

Presence of HLA-B*5701 allele. Prior hypersensitivity reaction to any of the components (see full labeling). Moderate or severe hepatic impairment.

Warnings/Precautions:

Screen for presence of HLA-B*5701 allele prior to starting therapy or reinitiation; if (+), abacavir is contraindicated. Discontinue immediately if hypersensitivity is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible. If hypersensitivity cannot be ruled out, do not restart. If stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed. Bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Not for treating hepatitis B; monitor patients co-infected with HBV for at least several months after stopping treatment (discontinuing may exacerbate HBV infection). Coronary heart disease. Diabetes. Smoking. Women, obesity, prolonged nucleoside exposure: increased risk of toxicity. Renal impairment (CrCl <50mL/min): not recommended. Mild hepatic impairment: use individual components if dose reductions are required. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

Concomitant stavudine, doxorubicin, ribavirin: not recommended. Abacavir may antagonize methadone. TMP/SMX, nelfinavir may potentiate lamivudine. Ethanol may potentiate abacavir. Atovaquone, fluconazole, methadone, nelfinavir, probenecid, rifampin, ritonavir, valproic acid may affect zidovudine levels; monitor. Increased hematologic toxicity with ganciclovir, other bone marrow suppressants or cytotoxic agents. Monitor for treatment-associated toxicities (esp. hepatic decompensation) with interferon-alpha with or without ribavirin.

Pharmacological Class:

Nucleoside analogues (reverse transcriptase inhibitors).

Adverse Reactions:

Nausea, headache, malaise, fatigue, vomiting; anemia, neutropenia, myopathy, myositis, fat redistribution, post-treatment exacerbation of hepatitis B, immune reconstitution syndrome, rash (may be severe, eg, Stevens-Johnson); hypersensitivity reactions (may be fatal), lactic acidosis, severe hepatomegaly with steatosis.

Note:

Register pregnant patients exposed to Trizivir by calling (800) 258-4263. Register patients who have had a hypersensitivity reaction to abacavir by calling (800) 270-0425.

How Supplied:

Tabs—60

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs